Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome

Kuo, Hann‐Chorng; Liu, Hsin-Tzu; Shie, Jia-Heng

doi:10.1016/j.tcmj.2012.10.005

Cited by 7 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant 3-fold elevation was also noticed in the urine levels of sIL-2Rα, and IL-10 in OAB patients. Another study demonstrated that C-reactive protein (CRP) was significantly higher in women with OAB associated with urgency incontinence, ( n = 30, 0.12 mg/dl) as compared to women with bladder oversensitivity ( n = 68, 0.075 mg/dl, P = 0.008) and nerve growth factor (NGF), IL-1β, IL-6, IL-8, and TNF-α levels were higher than the control group 58 , 59 . Further analysis revealed that body mass index and maximum flow rate were two independent factors that affected CRP levels.…”

Section: Mets-induced Inflammation Associated With Overactive Bladmentioning

confidence: 93%

See 1 more Smart Citation

Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links

Wang

Liu

et al. 2015

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

BackgroundEpidemiological data suggest that lower urinary tract symptoms (LUTS) may be associated with metabolic syndrome (MetS). Inflammation has been proposed as a candidate mechanism at the crossroad between these two clinical entities. The aim of this review article is to evaluate the role of MetS-induced inflammation in the pathogenesis and progression of LUTS.MethodsA systematic review was conducted using the keywords ‘metabolic syndrome AND lower urinary tract symptoms’ within the title search engines including PubMed, Web of Science, and the Cochrane Library for relevant research work published between 2000 and January 2015. The obtained literature was reviewed by the primary author (QH) and was assessed for eligibility and standard level of evidence.ResultsTotal of 52 articles met the eligibility criteria. Based on database search during the past 15 years and our systematic review of prospective and retrospective cohorts, case-control trials, observational studies and animal data identified a possible link between MetS-induced inflammation and LUTS including benign prostatic hyperplasia, bladder outlet obstruction, overactive bladder, urinary incontinence and others possible urinary tract abnormalities.ConclusionsThere is convincing evidence to suggest that MetS and inflammation could be important contributors to LUTS in men, particularly in the development of benign prostatic hyperplasia. However, the role of MetS-induced inflammation remains unclear in overactive bladder, urinary incontinence and etiology of LUTS progression.

show abstract

Section: Mets-induced Inflammation Associated With Overactive Bladmentioning

confidence: 93%

“…A few studies have investigated possible associations between MetS-induced inflammation and overactive bladder or urinary incontinence (UI). Some investigators have studied the role of urinary cytokines in patients with OAB 58 , 59 . Tyagi et al .…”

Section: Mets-induced Inflammation Associated With Overactive Bladmentioning

confidence: 99%

Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links

Wang

Liu

et al. 2015

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Correlation was found between IL-1β, IL-6 and IL-8 in the serum of patients and the existence of IC/BPS serum. The increased expression of IL-1β, IL-6, IL-8 in the serum of IC/BPS patients indicates that not only mast cell activation but also some other inflammatory mediators are involved in the pathogenesis of IC/BPS [ 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-inflammatory effects of lavender and eucalyptus essential oils on the in vitro cell culture model of bladder pain syndrome using T24 cells

Horváth

Pandur

Sipos

et al. 2022

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Interstitial cystitis (IC) has a chronic chemical irritation and inflammation of non-bacterial origin in the bladder wall leading to various severe symptoms. There is evidence that chronic inflammation is significantly associated with abnormal urothelial barrier function, epithelial dysfunction. This is the underlying cause of urothelial apoptosis and sterile inflammation. Method The anti-inflammatory effects of lavender and eucalyptus essential oils (EOs) and their main components (linalool and eucalyptol) were investigated in the T24 human bladder epithelial cell line on TNFα stimulated inflammation, at 3 types of treatment schedule. The mRNA of pro-inflammatory cytokines (IL-1β, IL-6, IL-8) were measured by Real Time PCR. Human IL-8 ELISA measurement was performed as well at 3 types of treatment schedule. The effects of lavender and eucalyptus EOs and their main components were compared to the response to NFκB inhibitor ACHP (2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-(4-piperidinyl)-3-pyridinecarbonitrile). Result There is no significant difference statistically, but measurements show that lavender EOs are more effective than eucalyptus EO. Long time treatment (24 h) of both lavender EO and linalool showed higher effect in decreasing pro-inflammatory cytokine mRNA expression than ACHP inhibitor following TNFα pre-treatment. Moreover, both lavender EOs were found to be significantly more effective in decreasing IL-8 secretion of T24 cells after TNFα pre-treatment compared to the ACHP NFκB-inhibitor. Conclusion The lavender EOs may be suitable for use as an adjunct to intravesical therapy of IC. Their anti-inflammatory effect could well complement glycosaminoglycan-regenerative therapy in the urinary bladder after appropriate pharmaceutical formulation.

show abstract

“…Studies have shown the anti-inflammatory mechanisms of HGF, wherein it reduces the production of pro-inflammatory cytokines mediated by macrophages and conversely enhances the secretion of adiponectin in adipocytes, thus further breaking the vicious cycle of inflammation mediated by the macrophages and adipocytes ( Coudriet et al, 2010 ; Shimizu et al, 2012 ; Kusunoki et al, 2014 ). Furthermore, Kuo et al (2013) demonstrated that the serum HGF elevation in patients with overactive bladder was associated with systemic neurotrophic factor elevation in the suburothelium of the bladder, which might play a role in the urgency and frequency sensory disorder ( Kuo et al, 2013 ). Several studies have also demonstrated that serum HGF elevation has been identified in patients with varying types of disorders, such as obesity, metabolic syndrome, diabetes mellitus, multiple myeloma, gastric cancer, and bladder cancer, indicating that HGF levels were associated with disease progression ( Oliveira et al, 2018 ; Wang et al, 2007 ; Corcoran et al, 2013 ; Sugimura et al, 1997 ).…”

Section: Discussionmentioning

confidence: 99%

A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome

et al. 2021

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a painful recurrent condition characterized by the discomfort of the bladder, and current treatment options have limited effectiveness. Prolotherapy is a well-known treatment that involves the injection of non-biologic solutions to reduce pain and/or promote proliferation of soft tissue, and dextrose is the most common injectate. This study investigated the effects of dextrose prolotherapy in a rat model of IC/BPS and patients with IC/BPS. We used cyclophosphamide to induce IC/BPS in rats, and intravesical instillation of 10% dextrose solution was performed. After 1 week, we conducted a urodynamic test, bladder staining, and ECM-related gene expression analysis to examine the treatment’s efficacy. We found that dextrose treatment could recover the instability of the bladder, reduce frequent urination, and improve the glycosaminoglycan layer regeneration and the bladder wall thickness along with a significant intense expression of CD44 receptors. Furthermore, we enrolled 29 IC/BPS patients with previous hyaluronic acid/Botox treatment for more than 6 months with remained unchanged condition. In this study, they received intravesical injections of 10% dextrose solution followed by assessments for up to 12 weeks. Patient characteristics and a 3-day voiding diary before treatment were recorded. Patient responses were examined using IC/BPS-related questionnaires. Moreover, expressions of growth factors and cytokines were analyzed. The results demonstrated that dextrose prolotherapy in patients with IC/BPS reduced the frequency of treatment over time, with the mean number of treatments being 3.03 ± 1.52, and significantly reduced the incidence of nocturia and questionnaire scores associated with symptoms. Dextrose prolotherapy significantly enhanced EGF level and, in contrast, reduced the level of HGF, PIGF-1, and VEGF-D after several weeks following treatment. The cytokine analysis showed that the expressions of IL-12p70 and IL-10 were significantly up-regulated after dextrose prolotherapy in IC/BPS patients. The levels of most growth factors and cytokines in IC/BPS patients had no significant difference and showed a similar tendency as time progressed when compared to healthy controls. Overall, the alteration of growth factors and cytokines exhibited safe treatment and potential stimulation of tissue remodeling. In summary, our study demonstrated that dextrose prolotherapy is a promising treatment strategy for IC/BPS disease management.

show abstract

Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome

Cited by 7 publications

References 38 publications

Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links

Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links

Anti-inflammatory effects of lavender and eucalyptus essential oils on the in vitro cell culture model of bladder pain syndrome using T24 cells

A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome

Contact Info

Product

Resources

About